This study is not yet accepting patients

Study With Phage for CF Subjects With Pseudomonas Lung Infection

a study on Chronic Pseudomonas Aeruginosa Infection Cystic Fibrosis Fibrosis

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The primary goal is to see if 8 weeks of twice daily BX004 can reduce the amount of PsA in the sputum compared to placebo (on top of background CF therapy).

Official Title

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects With Chronic Pseudomonas Aeruginosa (PsA) Pulmonary Infection

Details

This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate BX004 in CF subjects with chronic PsA pulmonary infection. The main purpose of the study is to evaluate whether BX004 reduces the PsA burden in the sputum of CF subjects with chronic PsA pulmonary infection. Secondary endpoints are to see how well BX004 works in improving lung function and quality of life, reducing the amount of PsA in the sputum, getting negative sputum cultures for PsA, and safety and tolerability. Clinically stable CF subjects with a confirmed diagnosis of CF and chronic PsA pulmonary infection will be enrolled. Subjects will be included in a 6-month post-dose safety follow-up. A Data Safety Monitoring Board of the CF Foundation will monitor safety.

Keywords

Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF), Infections, Communicable Diseases, Pseudomonas Infections, Cystic Fibrosis, Fibrosis

Eligibility

You can join if…

Open to people ages 18 years and up

  • Cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infection receiving standard of care inhaled antibiotics (cycling or continuous regimen) or no inhaled antibiotics
  • Age ≥ 18 years
  • FEV1 40%-80% predicted
  • Clinically stable lung disease
  • Willing and able to provide adequate sputum samples, using any method (spontaneously expectorated, induced, from home or clinic) at designated study visits.

You CAN'T join if...

  • Known hypersensitivity to bacteriophages or excipients in the formulation.
  • Receipt of prior bacteriophage therapy within the 6 months prior to Screening or Day 1
  • Detection of Burkholderia cenocepacia from respiratory tract within 1 year prior to Screening or from Screening culture
  • Currently receiving systemic treatment for allergic bronchopulmonary aspergillosis
  • Currently receiving treatment for active infection with non-tuberculous mycobacteria or prior detection of Mycobacterium abscessus in 12 months prior to Screening
  • History of severe neutropenia
  • History of lung transplant
  • History of solid organ transplant
  • Acquired or primary immunodeficiency syndrome
  • Initiation or change in type of CFTR modulator less than 3 months prior to Screening
  • Pregnant or breastfeeding female

Locations

  • UCSF
    San Francisco California 94143 United States
  • Stanford University
    Palo Alto California 94061 United States

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
BiomX Ltd
ID
NCT06998043
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 63 study participants
Last Updated